Philips and NLC recently teamed up to create new ventures based on Philips’ IP. The second venture that originated from that collaboration is Respiosa, which is operating in the obstructive sleep apnea (OSA) field. OSA is characterized by repetitive narrowing and collapse of the upper airway during sleep, which leads to oxygen desaturation and fragmented sleep. Approximately two million people are diagnosed suffering from OSA each year. Respiosa is helping these patients by developing a simple, minimally invasive surgical implant to provide optimal therapy for tongue-based OSA. Respiosa is led by Jaap Delange, who brings more than 30 years of experience in medtech.